Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 48Lymphoid 46Myeloid 34Plasma cell 33Sarcoma 30Dermatologic 20Classical hematology 16Genitourinary 5Other neoplasm 4CNS 3Head & Neck 2Breast 2Thoracic 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 4Breast Neoplasms 4Stomach Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasm Metastasis 3Melanoma 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neuroendocrine Tumors 2Mesothelioma 2Colorectal Neoplasms 2Adenocarcinoma of Lung 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neoplasms, Squamous Cell 1Neoplasms 1Microsatellite Instability 1Mesothelioma, Malignant 1Meningioma 1

Interventions

Docetaxel 8pembrolizumab 7Pemetrexed 5Carboplatin 5Erlotinib Hydrochloride 4toripalimab 3rociletinib 3fludarabine 3Radiosurgery 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Gemcitabine 3Etoposide 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3lorlatinib 2atezolizumab 2Vinorelbine 2Topotecan 2Radiotherapy 2Platinum 2Itraconazole 2Irinotecan 2Interleukin-2 2Cetuximab 2Albumin-Bound Paclitaxel 2vinflunine 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × fludarabine phosphate × Thoracic × Clear all
NCT03215810 2023-07-24

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
20 enrolled 10 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Recurrence, Carcinoma, Adenosquamous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡